The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Smart move, just tuck them away. If you look at the chart the pattern is clear ie 4-5 low and 10p high. No doubt this will happen again in 2024. Angus mentioned profitable from H2 2024 and shares always move on expectation of such news, he also mentioned that the legacy pre ACRM sellers have liquidated in 2023 and that was a key drag which is now no more. Enough from me, time to accumulate and sit back patiently as we know SAAS businesses like this should be valued as per Angus 6-9x revenues not 1-2x DYOR
Looked at the RNS again, just extrapolate: As at 12 January 2024 the bank cash balance £901,000.Forward contracted revenue as at 31 December 2023 £2.9m. MCAP only £5.7mio and no debt. Legacy shareholders exited in 2023, most shares now in strong hands, the re-rate might be slow as still under the radar, but we know it will come from 5p and we will revisit the previous 10p highs DYOR
Great update and definitely 2024 should be a turning point for such a small cap revenue generating #ACRM
Just listened to the latest interview over the festive season, 2024 should be very interesting https://audioboom.com/posts/8421293-12-stocks-for-the-12-days-of-christmas-featuring-angus-forrest-chairman-and-kerry-chambers-ceo
Just bought 10mio shares (shows as a sale). Looks to me that this 0.085 area is the 'low' you can buy for now. Well stimulation should start Monday and last only a week with results not long thereafter. Stimulation should clearly increase flows although nobody knows to what level. From the 13.11.23 RNS they mentioned that the rod pump can handle up to 250bopd max which would be a significant increase from current level, which is already commercial. They also quoted that the rod pump will be replaced with an ESP in the middle of the first quarter of 2024 (mid Feb?) which has the capacity to optimise initial production from the well and increase flows further. Who knows, but it could be that the ESP installation is delayed but in any case the facts as they stand are that we found more oil than initially planned, that we are already commercial and that have funds for the stimulation process which will increase flow rates. Looks to me that the upside from here is greater than the downside risks but nothing is guaranteed in this sector, therefore reach your conclusions and as usual DYOR
Just to be factual, the new chairman did buy shares in the market as per 1 December RNS
I'm still convinced that people such as our new Chariman recently appointed wouldn't get involved into a small cap with a £1mio mcap unless they already had a clear plan. In the 30.11.23 he stated: 'The funding will also allow us to have further working capital as we begin to look at other exciting opportunities within the sector which I am keen to integrate as part of Global's portfolio of assets with this process starting shortly. Delivering long term shareholder value is fundamental for us as a new board.' All speculations at this stage, but maybe they were just after a shell for other assets by the looks DYOR https://www.apexgroup.com/insights/apex-group-consolidates-advisory-capital-raising-offering-with-new-appointment/
Interesting RNS, always good for other brokers and their clients to get involved
Mcap on listing of £6.8mio vs Optiva NPV15 of £81mio. 85% of holders locked in. Should do well from such a discounted 4p placing DYOR
Great news, very exciting especially when coupled with the small mcap. As usual we will see short term churn and once done we will move higher to close the chart gap. The concern with any small cap is funding and that is now out of the way. I have observed many companies trying to raise in this market, some cancel the raise as there is no interest, others raise but at the low end of what they were seeking and only a few managed to raise what they were aiming at and RUA has done that, highlighting the retail and institutional interest in the stock and its potential. DYOR
As expected: 'The Exchange will restore RUA Life Sciences PLC to trading on 19 December 2023 with the restoration taking place at 07:30'.
Getting very interesting on various fronts, well done #ACRM "We are delighted that a leading cyber security consultancy has chosen STREAM® as a key tool for its own business and look forward to working with them and potentially many of their clients in the future
Very good interview with our Chairman https://twitter.com/RoastPR/status/1735241668050215234
As seen with AMTE raise, some institutions have sold shares ahead of the GM and couldn't settle their trades, hence suspension until GM and/or share admission. GM here is at 11am on 18.12, so as a guess shares will relist either that day after GM or more likely at 8am on Tuesday 19. 12. when new shares are admitted. If my assumption is correct some of the shares from the placing have already been flipped. Half Year results also Monday 18.12. They are now more than funded so that concern is no longer, personally think that once churn is done, and some has probably already happened, the shares will move up as the risk reward seems very interesting. These are all guesses so let's wait and see what happens. DYOR
Interesting tweet by the company:
Afentra PLC are delighted to note that Peel Hunt’s research highlights the increase in NAV driven by the improved fiscal terms of the producing assets. The Core/Risked NAV have experienced a substantial rise, increasing from 32/60p to 46/78p.
My guess is that some institutions sold shares from the raise which they can't settle as subject to GM 18 December. DYOR
N05/23 - RUA Life Sciences PLC - Suspension of trading and settlement situation
1. London Stock Exchange ("the Exchange") has been monitoring the settlement situation in RUA Life Sciences PLC (ISIN: GB0033360586) following the Company's recent notification in relation to the issue of new shares which are conditional on shareholder consent. As a result of the deterioration in settlement performance, the trading of RUA Life Sciences PLC shares has been temporarily suspended under Rule 1510 of the Rules of the London Stock Exchange. Settlement of outstanding transactions can continue whilst the security is suspended. The Exchange will continue to monitor the settlement situation and when trading is to be restored, the market will be notified by Stock Exchange Notice.
2. Rule 5000 (Obligation to settle) and its associated guidance places an obligation on member firms to ensure that every on Exchange trade is duly settled on the agreed settlement date. This obligation remains even if the reason for non-settlement is a customer or counterparty having failed to settle other transactions in the same security.
3. Any queries on this Notice should be addressed to Market Supervision, Market Regulation, telephone +44 (0)20 7797 3666 (STX 33666) option 2.
Time will tell, but the price move suggests that we have bottomed and that the market knows that news on a new contract is imminent. Hopefully bigger than the small ones seen.
Agreed. Plus not many small cap can raise that amount of money in this market, if institutional and professional investors have taken the raise they must think that the revised strategy provides a compelling risk reward from 11p DYOR
Fully agree, but hopefully he will add more. I have followed GBP for its potential for a long time, although it became clear that the previous leadership was not delivering. There is absolutely no certainty that the incoming team will deliver, but remain of the idea that people with those CVs, and probably significant wealth accumulated in their career, would not come into GBP unless they thought that the current assets could be worth than the company valuation and/or the limited market cap make it an interesting proposition to drop in other assets. Nobody really know and only time will tell but those are my impressions. Furthermore, why would the current board transition out so smoothly unless they thought there could be some upside for them and shareholders in general. A shareholder with 5% cannot boot them out and usually it's actually the opposite, massive resistance from the board not to loose their positions. DYOR